NUCKS1 Knockout Raji Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal cell population derived from the Raji human B lymphocyte line, featuring targeted disruption of the NUCKS1 gene. As a pooled knockout model, this product provides a heterogeneous cell mixture with gene editing across the population, enabling functional studies without the limitations of clonal isolation. This loss?of?function system is designed to interrogate NUCKS1?dependent molecular mechanisms in B?cell biology and lymphomagenesis.
The Raji cell line, isolated from a Burkitt lymphoma, is an Epstein?Barr virus (EBV)?positive B lymphocyte model that retains key features of humoral immunity, including surface immunoglobulin expression and antigen presentation capacity. Raji cells display a mature B?cell phenotype and are extensively used to investigate B?cell malignancies, virus?host interactions, and oncogenic signaling. Their EBV?transformed nature confers robust proliferative and survival characteristics, making them particularly suitable for studying pathways that govern lymphoma cell growth and apoptosis.
NUCKS1 is a nuclear DNA?binding protein that functions as a transcriptional regulator, integrating signals from cell cycle kinases and DNA damage sensors. It is directly phosphorylated by CDK1 and CK2, linking its activity to cell cycle progression. In response to genotoxic stress, NUCKS1 participates in the ATM?CHK2 signaling axis and interacts with PARP1, p53, and the NF???B subunit RelA/p65. Through these associations, NUCKS1 modulates expression of key downstream targets, including the cyclin D1 gene (CCND1), which promotes G1/S transition, and the anti?apoptotic factor BCL2, thereby influencing cell survival and proliferation. Additionally, NUCKS1?mediated regulation of NF???B signaling further connects DNA damage responses to transcriptional control of inflammatory and survival genes.
In the Raji B?cell context, disruption of NUCKS1 is expected to perturb the interplay between DNA repair, NF???B transcriptional networks, and apoptotic thresholds. Given that Raji cells harbor constitutive NF???B activity and rely on EBV?encoded survival factors, NUCKS1 knockout may impair DNA damage resolution and sensitize cells to chemotherapeutic agents or stress?induced apoptosis. This model thus enables dissection of NUCKS1 contributions to Burkitt lymphoma maintenance and offers a platform to evaluate its role in chemoresistance and EBV?driven oncogenic signaling.
Typical applications include mechanistic studies of B?cell lymphoma pathogenesis, DNA damage repair pathways, and chemoresistance using a suite of biochemical and functional assays. Recommended techniques include Western blotting and RT?qPCR for confirming NUCKS1 ablation, RNA?seq for transcriptome?wide analysis, flow cytometry for cell cycle and apoptosis profiling, co?immunoprecipitation to assess interactions with PARP1 or RelA/p65, ChIP?qPCR to map NUCKS1 promoter occupancy, NF???B luciferase reporter assays to quantify pathway activity, and drug sensitivity assays employing etoposide to evaluate chemoresistance. For further technical details or to discuss your experimental needs, please contact Ascent Research.
